(134 days)
No
The summary describes a device that combines standard physiological measurements (CO2, SpO2, pulse rate, respiration rate) and calculates an "Integrated Pulmonary Index" (IPI) based on these parameters. The description of the IPI calculation does not suggest the use of AI/ML; it appears to be a deterministic calculation based on the input values. There are no mentions of AI, ML, deep learning, training data, or performance metrics typically associated with AI/ML models.
No
The device is described as a monitor and analyzer, providing continuous measurements and alerts, which are diagnostic and monitoring functions, not therapeutic interventions.
No
The device is a monitor that measures physiological parameters (carbon dioxide concentration, respiration rate, oxygen saturation, and pulse rate) and displays an integrated pulmonary index (IPI). While the IPI alerts clinicians to changes in a patient's pulmonary status, it is explicitly stated to be "an adjunct to, and is not intended to replace, vital sign monitoring." This indicates it provides information to support clinical assessment rather than making a definitive diagnosis.
No
The device description explicitly states it is a "bedside monitor" consisting of hardware modules (CO2 capnography module and pulse oximetry module) implemented in a "host device." While it uses software, it is not solely software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The Capnostream20 monitor measures and monitors physiological parameters directly from the patient's body (expired breath for CO2 and respiration rate, and arterial hemoglobin for SpO2 and pulse rate). It does not analyze samples taken from the body.
- Classification: The device is classified under 21 CFR § 868.1400 (Carbon Dioxide Analyzer) and 21 CFR § 870.2700 (Pulse Oximeter). These classifications fall under medical devices that monitor physiological functions in vivo, not in vitro.
The device is a patient monitoring device that provides real-time physiological data, which is distinct from an in vitro diagnostic device that analyzes biological samples.
N/A
Intended Use / Indications for Use
The Capnostream20 combined capnograph/pulse oximeter monitor is intended to provide professionally trained health care providers the continuous, non invasive measurement and monitoring of carbon dioxide concentration of the expired and inspired breath and respiration rate, and for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate. It is intended for use with neonatal, pediatric and adult patients in hospitals, hospital type facilities, intra hospital transport and home environments.
The Capnostream20 monitor provides the clinician with an integrated pulmonary index (IPI). The IPI is based on four parameters provided by the monitor: end tidal carbon dioxide, respiration rate, oxygen saturation and pulse rate. The IPI is a single index of an adult or pediatric patient's ventilatory status displayed on a scale of 1 - 10, where 10 indicates optimal pulmonary status. IPI monitoring displays a single value that represents the patient's pulmonary parameters and alerts clinicians to changes in the patient's pulmonary status.
The IPI is an adjunct to, and is not intended to replace, vital sign monitoring.
Product codes
CCK
Device Description
The Capnostream20 bedside monitor is a two parameter monitor consisting of a CO2 capnography module and a pulse oximetry module implemented in a host device. The host device displays parameters received from the respective modules and generates alarms when preset alarm thresholds are crossed. The device is classified as CCK Class II according to 21 CFR § 868.1400 - Carbon Dioxide Analyzer with DQA 21 CFR § 870.2700 Pulse Oximeter listed as an additional or alternate classification.
This device has two modules that are classified as follows:
- 21 CFR 868.1400, Carbon Dioxide Analyzer (Classification CCK) .
- 21 CFR 870.2700 Pulse Oximeter (Classification DQA) .
Each module is controlled by dedicated software that is an integral part of the respective module.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
neonatal, pediatric and adult patients
Intended User / Care Setting
professionally trained health care providers. It is intended for use with neonatal, pediatric and adult patients in hospital type facilities, intra-hospital transport and home environments.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 868.1400 Carbon dioxide gas analyzer.
(a)
Identification. A carbon dioxide gas analyzer is a device intended to measure the concentration of carbon dioxide in a gas mixture to aid in determining the patient's ventilatory, circulatory, and metabolic status. The device may use techniques such as chemical titration, absorption of infrared radiation, gas chromatography, or mass spectrometry.(b)
Classification. Class II (performance standards).
0
SPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediCO2 CO2 module 510(k) Summary of Safety and Effectiveness 1094012
7. 510(k) Summary of Safety and Effectiveness
This summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92
(This section is not confidential)
MAY 1 2 2010
: "!
DATE THIS SUMMARY WAS PREPARED
December 15th, 2009
SUBMITTER'S NAME AND ESTABLISHMENT ADDRESS:
Oridion Capnography Inc. 160 Gould Street Needham, MA 02494
ESTABLISHMENT REGISTRATION NUMBER
3003941644
CONTACT PERSON:
Rachel Weissbrod, Director of Regulatory Affairs Oridion Medical 1987 Ltd. Har Hotzvim Science Park POB 45025 91450 Jerusalem, Israel Telephone: 857-919-2923 Fax: +972-2-586-6680 Email: rachel.weissbrod@oridion.com
DEVICE INFORMATION
Trade Name: Capnostream20 Common Name: Two Parameter Bedside Monitor Classification Name: Capnograph/Pulse Oximeter Regulation Number: 868.1400, Carbon Dioxide Analyzer (Classification CCK) 870.2700 Pulse Oximeter (Classification DQA) Device Listing Number: D001115.
1
SPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediCO2 CO2 module 510(k) Summary of Safety and Effectiveness
PREDICATE DEVICE
Capnostream20 with the microMediCO2 CO2 board is substantially equivalent to the following commercially available device:
| Manufacturer | Device | 510(k)No. | Clearance Date |
|---|---|---|---|
| Oridion 1987 Medical Ltd | Capnostream20 | K082268 | February 9th, 2009 |
DEVICE DESCRIPTION
The Capnostream20 bedside monitor is a two parameter monitor consisting of a CO2 capnography module and a pulse oximetry module implemented in a host device. The host device displays parameters received from the respective modules and generates alarms when preset alarm thresholds are crossed. The device is classified as CCK Class II according to 21 CFR § 868.1400 - Carbon Dioxide Analyzer with DQA 21 CFR § 870.2700 Pulse Oximeter listed as an additional or alternate classification.
This device has two modules that are classified as follows:
- 21 CFR 868.1400, Carbon Dioxide Analyzer (Classification CCK) .
- 21 CFR 870.2700 Pulse Oximeter (Classification DQA) .
Each module is controlled by dedicated software that is an integral part of the respective module.
INTENDED USE
The Capnostream20 combined capnograph/pulse oximeter monitor is intended to provide professionally trained health care providers the continuous, non invasive measurement and monitoring of carbon dioxide concentration of the expired and inspired breath and respiration rate, and for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpQ₂) and pulse rate. It is intended for use with neonatal, pediatric and adult patients in hospital type facilities, intra-hospital transport and home environments.
The Capnostream20 monitor provides the clinician with an integrated pulmonary index (IPI). The IPI is based on four parameters provided by the monitor: end tidal carbon dioxide, respiration rate, oxygen saturation and pulse rate. The IPI is a single index of an adult or pediatric patient's ventilatory status displayed on a scale of 1 - 10, where 10 indicates optimal pulmonary status. IPI monitoring displays a single value that represents the
2
SPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediCO2 CO2 module 510(k) Summary of Safety and Effectiveness o ratient's pulmonary parameters and alerts clinicians to changes in the patient's pulmonary status.
The IPI is an adjunct to, and is not intended to replace, vital sign monitoring
COMPARISON TO PREDICATE DEVICE
The Capnostream20 with the micromediCO2 CO2 module is substantially equivalent to the predicate Capnostream20 with the minimediCO2 CO2 module.
The new device meets the safety and performance standards met by the predicate device.
The functional features and the intended use of the Capnostream20 with the new CO2 module are substantially equivalent to the predicate device. No significant changes were made to the monitor hardware or software specifications to support the integration of the new module. Slight mechanical changes were made to the monitor to accommodate the smaller dimensions of the new module. The micromediCO2 module is smaller in size than the miniMediCO2 module, in order to facilitate integration inside other OEM monitors, and provides enhanced processing and memory capacity, to support software applications for future development. The module provides the following inputs to the host monitor:
FiCO2, EtCO2 numeric, EtCO2 waveform, Respiratory Rate, IPI (Integrated Pulmonary Index), and continuous CO2 numeric and waveform.
The micromediCO2 includes a smaller lamp, a new solenoid, broader use of molded parts to improve production quality, increased processing power, reduced power consumption and improved flow regulation.
The module software provides full backward compatibility with the miniMedicO2 and supports RS232 or USB communication with the host monitor.
A hazard analysis was carried out on the module and on the Capnostream20 monitor with the new module. This hazard analysis concluded that any residual risks were judged as acceptable when weighed against the intended benefits of use of the system. Verification and validation of the new module as a standalone and when integrated in the monitor were successfully completed.
3
. '
| Attribute | Capnostream20 Bedside
Monitor with
microMediCO2CO2 module | Predicate Device- Capnostream20
Bedside Monitor K082268 |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications for
use | The indications for use are identical to
the indications for use in the predicate
device | The Capnostream20 combined
capnograph/pulse oximeter monitor is intended
to provide professionally trained health care
providers the continuous, non invasive
measurement and monitoring of carbon
dioxide concentration of the expired and
inspired breath and respiration rate, and for
the continuous non-invasive monitoring of
functional oxygen saturation of arterial
hemoglobin (SpO2 and pulse rate). It is
intended for use with neonatal, pediatric and
adult patients in hospitals, hospital type
facilities, intra hospital transport and home
environments. |
| Target
population | It is intended for use with neonatal,
pediatric, and adult patients. | It is intended for use with neonatal, pediatric,
and adult patients. |
| Design | Identical to the Capnostream20
described in K082268 with the
exception of the introduction of the
micromediCO2 CO2 module | See K082268 |
| Where Used | It is to be used by physicians, nurses
and other trained health care
providers in critical care patient
settings, such as anesthesiology,
intensive care medicine, neonatal
intensive care and other health care
areas. | It is to be used by physicians, nurses and
other trained health care providers in critical
care patient settings, such as anesthesiology,
intensive care medicine, neonatal intensive
care and other health care areas. |
| Performance
Standards | ISO 21647
ISO 9919 | ISO 21647
ISO 9919 |
| Safety
Standards | IEC/EN 60601-1
IEC/EN 60601-1-2
IEC 60601-1-8
UL 60601-1
ISO 14971 | IEC/EN 60601-1
IEC/EN 60601-1-2
IEC 60601-1-8
UL 60601-1
ISO 14971 |
| Biocompatibility | There are no issues of
biocompatibility for this device and no
biocompatibility testing was done. | There are no issues of biocompatibility for this
device and no biocompatibility testing was
done. |
| Sterility | This device does not require
sterilization and is shipped marked
non-sterile. | This device does not require sterilization and is
shipped marked non-sterile. |
4
SPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediCO2 CO2 module 510(k) Summary of Safety and Effectiveness
CONCLUSION
Capnostream20 with the micromediCO2 CO2 module does not raise any new potential safety risks and is equivalent in performance to the existing legally marketed device. Therefore, the device is substantially equivalent to the predicate device with respect to safety, effectiveness, and intended use.
5
Image /page/5/Picture/0 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with three swooping lines representing its wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room-WO66-G609 Silver Spring, MD 20993-0002
MAY 12 2010
Ms. Rachel Weissbrod Director of Regulatory Affairs Oridion Capnography, Incorporated 160 Gould Street Needham, Massachusetts 02494
Re: K094012
Trade/Device Name: Capnostream20 with Micromedico2 Module Regulation Number: 21 CFR 868.1400 Regulation Name: Carbon Dioxide Gas Analyzer Regulatory Class: II Product Code: CCK Dated: April 13, 2010 Received: April 15, 2010
Dear Ms. Weissbrod:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
6
Page 2- Ms. Rachel Weissbrod
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to
http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Nh for
Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure
7
SPECIAL-510(k) Submission for CAPNOSTREAM20 two parameter bedside monitor with microMediCO2 CO2 module Statement of Indications for Use
6. Statement of Indications for Use
TWO PARAMETER CAPNOSTREAM MONITOR (This document is not confidential) Indications for Use
December 15th, 2009
Ko94012 510(k) Number (if known)
Device Name: Capnostream 20
Indications for Use:
The Capnostream20 combined capnograph/pulse oximeter monitor is intended to provide professionally trained health care providers the continuous, non invasive measurement and monitoring of carbon dioxide concentration of the expired and inspired breath and respiration rate, and for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate. It is intended for use with neonatal, pediatric and adult patients in hospitals, hospital type facilities, intra hospital transport and home environments.
The Capnostream20 monitor provides the clinician with an integrated pulmonary index (IPI). The IPI is based on four parameters provided by the monitor: end tidal carbon dioxide, respiration rate, oxygen saturation and pulse rate. The IPI is a single index of an adult or pediatric patient's ventilatory status displayed on a scale of 1 - 10, where 10 indicates optimal pulmonary status. IPI monitoring displays a single value that represents the patient's pulmonary parameters and alerts clinicians to changes in the patient's pulmonary status.
The IPI is an adjunct to, and is not intended to replace, vital sign monitoring.
Prescription Use X (Per 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
L. Schull
(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices
510(k) Number: K094012
Page 9